AbbVie (ABBV) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.
Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.Sale Jeffrey Ryan Stewart, Evp, Chief Commercial Officer sold 40,619 shares at $293.60 ($11.9M).
- Trade date
- Nov 9, 2026
- Disclosed to the SEC
- Nov 12, 2026
- Type
- Sale (code S)
Read the original SEC filing ↗All ABBV insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
ABBV insider transactions (Form 4)
Open-market purchases and sales. 64 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 12SEC | Jeffrey Ryan StewartEvp, Chief Commercial Officer | Sell | 40,61983,171 held (−33%) | $293.60 | $11.9M | -1.7% | — |
| Aug 18SEC | Nicholas DonoghoeEvp, Chief Bus/Strat Officer | Sell | 32,71074,430 held (−31%) | $250.00 | $8.2M | +15.4% | — |
| Mar 6SEC | David Ryan PurdueSvp, Controller | Sell | 5,2302,654 held (−66%) | $233.56 | $1.2M | +23.6% | — |
| Mar 3SEC | Perry C. SiatisEvp, Gc And Secretary | Sell Plan | 10,2917,219 held (−59%) | $234.66 | $2.4M | +23.0% | — |
| Mar 3SEC | Perry C. SiatisEvp, Gc And Secretary | Sell Plan | 5,77717,510 held (−25%) | $233.51 | $1.3M | +23.6% | — |
| Mar 3SEC | Perry C. SiatisEvp, Gc And Secretary | Sell Plan | 2,6004,619 held (−36%) | $235.26 | $612K | +22.7% | — |
| Feb 27SEC | Perry C. SiatisEvp, Gc And Secretary | Sell Plan | 22,38138,137 held (−37%) | $230.00 | $5.1M | +25.5% | — |
Similar past setups: not applicable. ABBV has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with ABBV in the Research Lab
ABBV has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
AbbVie insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 4 sold $30.8M of ABBV stock on the open market; P/E 62.3 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
ABBV insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $11.9M | 1 |
| Q3 2026 | — | 0 | $8.2M | 1 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | — | 0 | $10.7M | 5 |
Valuation, profit and volume
Source: SEC filings, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 AbbVie insiders reported open-market purchases totaling $0, while 4 insiders reported sales totaling $30.8M. 4 of 7 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
ABBV earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Oct 30, 2026 | +3.2% | None | -0.7%S&P -2.2% | pending |
| Oct 5, 2026 | -0.5% | None | +1.5%S&P +1.2% | +8.7% |
| Jul 31, 2026 | +5.4% | None | -4.8%S&P +2.2% | +6.8% |
| Jul 6, 2026 | +18.0% | None | -2.5%S&P +0.4% | -3.6% |
| Apr 29, 2026 | -3.5% | None | +6.9%S&P +1.0% | +3.0% |
| Apr 3, 2026 | +0.2% | Sold $1.2M | -1.0%S&P +0.5% | +0.0% |
| Feb 4, 2026 | +5.3% | None | -2.9%S&P -1.7% | +5.1% |
| Jan 7, 2026 | -1.7% | None | +0.1%S&P -0.3% | +0.5% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
ABBV short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded ABBV
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Alan ArmstrongSenate | Bought $15,001 - $50,000 | Mar 27, 2026 | Jul 21, 2026 | +40.0% |
| John BoozmanSenate | Sold $1,001 - $15,000 | Aug 22, 2025 | Sep 12, 2025 | +41.3% |
| John BoozmanSenate | Sold $1,001 - $15,000 | Aug 11, 2025 | Sep 12, 2025 | +49.8% |
Insiders at AbbVie
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Jeffrey Ryan StewartEvp, Chief Commercial Officer | — | $11.9M | Nov 12, 2026 | — | — |
| Perry C. SiatisEvp, Gc And Secretary | — | $9.5M | Mar 3, 2026 | — | — |
| Nicholas DonoghoeEvp, Chief Bus/Strat Officer | — | $8.2M | Aug 18, 2026 | — | — |
| David Ryan PurdueSvp, Controller | — | $1.2M | Mar 11, 2026 | — | — |
| Azita SalekiEvp, Chief Operations Officer | — | — | Nov 18, 2026 | — | — |
| Roxanne S. AustinDirector | — | — | May 12, 2026 | 2 of 2 | — |
| Edward J. RappDirector | — | — | May 12, 2026 | 1 of 1 | — |
| Thomas J. FalkDirector | — | — | May 12, 2026 | — | — |
| Frederick H. WaddellDirector | — | — | May 12, 2026 | — | — |
| Thomas C. FreymanDirector | — | — | May 12, 2026 | — | — |
| Rebecca B. RobertsDirector | — | — | May 12, 2026 | — | — |
| Brett J. HartDirector | — | — | May 12, 2026 | — | — |
| William H.L. BurnsideDirector | — | — | May 12, 2026 | — | — |
| Melody B. MeyerDirector | — | — | May 12, 2026 | — | — |
| Jennifer L. DavisDirector | — | — | May 12, 2026 | — | — |
| Susan E. QuagginDirector | — | — | May 12, 2026 | — | — |
| Demetris D. CrumEvp, Chief Hr Officer | — | — | Mar 6, 2026 | — | — |
| Robert A. MichaelCEO, Chair | — | — | Mar 3, 2026 | — | — |
| Scott T. ReentsCFO | — | — | Mar 3, 2026 | — | — |
| Roopal ThakkarEvp, R&D And Cso | — | — | Mar 3, 2026 | — | — |
Board links: companies that share insiders with ABBV
Directors and executives who filed Form 4s for ABBV and another company in the last 12 months.
- CRWDCrowdStrike Roxanne S. Austin Director here · Director at CRWD · latest filing Sep 15, 2026
- PGProcter & Gamble Jennifer L. Davis Director here · CEO at PG · latest filing May 12, 2026
- UALUnited Airlines Brett J. Hart Director here · President at UAL · latest filing Nov 3, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
ABBV stock: common questions
Are AbbVie insiders buying ABBV stock?
No. No AbbVie insider reported an open-market purchase of ABBV in the past 12 months.
Are AbbVie insiders selling ABBV stock?
4 insiders reported sales worth $30.8M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ABBV's P/E ratio?
ABBV trades at about 62.3 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is ABBV's 52-week range?
Over the past year ABBV has traded between $195.99 and $295.03. It last closed at $288.62 on Nov 20, 2026.